证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20260101 投资者关系活 动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 时间 2025 年 12 月 26 日 地点 宝莱特公司会议室 参与单位名称 东方证券 胡葵、罗帆、黄建秋、卢雯等参加东方证券"走进上市公司活 动——宝莱特"的投资者。 上市公司接待 人员姓名 董事会秘书 杨永兴 证券事务代表 李韵妮 证券事务专员 钟欣昊 投资者关系活 动主要内容介 绍 一、公司介绍 宝莱特成立于 1993 年，主营业务为医疗器械产品的研发、生产、销 售。公司作为中国最早一批研发制造医疗监护仪的民族企业，是国家发改 委授予的"国家多参数监护仪产业化基地"、工业和信息化部认定的"第八 批国家级制造业单项冠军企业"，目前公司的监护设备已覆盖数千家医疗 机构。 在生命信息与支持领域，公司的监护产品品类丰富，公司拥有一体式 监护仪、插件式监护仪和掌上监护仪三大系列产品，以及输注液泵、心电 图机、中央监护系统等院内医疗设备及配套产品，广泛应用于普通病房、 急诊室、ICU、CCU、 ...

Investment Rating - The report maintains a "Buy" rating for the company [1][8] Core Insights - The company reported a significant revenue growth of 39.79% year-on-year, reaching 584 million yuan for the first three quarters of 2025, with a net profit increase of 68.68% to 104 million yuan [4][8] - In Q3 2025, the company achieved a revenue of 227 million yuan, marking a 61.66% increase year-on-year, and a net profit of 49 million yuan, which is a remarkable growth of 205.50% [4][8] - The growth in revenue is attributed to accelerated industry procurement and an increase in market share, particularly in equipment sales and self-produced consumables [4][5] Summary by Sections Financial Performance - For the first three quarters of 2025, the company’s gross margin increased by 0.98 percentage points to 48.52% [7] - The company’s self-produced consumables revenue reached 65 million yuan in the first half of 2025, a year-on-year increase of 91.90% [6] - The projected revenues for 2025-2027 are 797 million, 1,015 million, and 1,264 million yuan, with corresponding net profits of 160 million, 209 million, and 267 million yuan, indicating growth rates of 125.81%, 30.51%, and 27.69% respectively [8][11] Market Position - As of September 2025, the company holds a market share of 21.74% in the blood dialysis machine sector, ranking first in the industry [5] - The company’s market share for Continuous Renal Replacement Therapy (CRRT) is 18%, maintaining its leading position [5] Future Outlook - The company is expected to continue its growth trajectory, with revenue forecasts showing a compound annual growth rate (CAGR) of 40.50% for 2025 [8][11] - The earnings per share (EPS) are projected to increase from 0.50 yuan in 2025 to 0.83 yuan in 2027, reflecting a positive outlook for profitability [8][11]

Group 1 - The core announcement from China Europe Fund is the suspension of large subscriptions, conversions, and regular investment for the China Europe Medical Innovation Equity Fund starting from August 11, 2025, with a daily limit of 100,000 yuan per account to ensure fund stability and protect the interests of fund shareholders [1][3][10] - The China Europe Medical Innovation Fund, established in February 2019 and managed by fund manager Ge Lan, primarily invests in stocks related to the medical innovation sector, aiming to achieve returns that exceed the performance benchmark while strictly controlling investment risks [1][3][5] - As of mid-2023, the fund's total net asset value exceeded 8.2 billion yuan, with major investments in healthcare and manufacturing sectors, accounting for 46.41% and 41.99% of the total assets, respectively [4][5] Group 2 - The top ten holdings of the fund include companies such as 3SBio, Kelun-Biotech, and Kangfang Biotech, with the largest holding, 3SBio, showing a remarkable increase of nearly 400% this year [4][6][8] - The fund's unit net value has been on the rise, reaching 1.6874 yuan, significantly up from below 0.9 yuan a year ago, reflecting the rebound in the innovative drug sector [7][8] - The fund's outlook for the third quarter highlights optimism in the innovative drug field, with expectations for global cooperation and important clinical data disclosures, alongside supportive domestic policies for high-quality development in innovative drugs [8]